A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer - Trial NCT06347705
Access comprehensive clinical trial information for NCT06347705 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 99 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Memorial Sloan Kettering Cancer Center
Timeline & Enrollment
Phase 2
Mar 28, 2024
Mar 28, 2029
Primary Outcome
Number of participants with a complete response or minimal residual disease.
Summary
The purpose of this study is to see whether combining 2141-V11 with various standard
 treatments is an effective treatment approach for prostate cancer. 2141-V11 works by
 activating the immune system to find and kill cancer cells. Researchers will look at whether
 this treatment approach is able to completely get rid of cancer in participants, and they
 will check for the presence of minimal residual disease (MRD) in participants. MRD is a small
 number of cancer cells that can be detected in the body after treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06347705
Non-Device Trial